Skip to content
    ROIV
    Earnings call· Jun 2026(Q1 FY27)

    Roivant Sciences Q1 FY27 earnings call ROIV

    Aug 6, 2026 Source

    Executive summary

    Roivant Q1 FY27 — Brepocitinib DM Launch Imminent, Robust Pipeline Catalysts Ahead

    Roivant is entering a period of significant catalysts, highlighted by the imminent potential launch of brepocitinib for dermatomyositis and multiple pipeline data readouts in the second half of 2026. The company is strategically preparing for a "slow and steady" launch for brepocitinib, focusing on long-term market development across multiple indications. Financial strength was bolstered by a $950 million Moderna settlement payment, enabling substantial share repurchases, while R&D investments continue to drive a rich pipeline with numerous potential registrational events and filings anticipated through 2028.

    Highlights

    4

    • Brepocitinib launch in dermatomyositis (DM) is on track for imminent potential approval and launch by end of September 2026.

    • Initiated Phase III study for brepocitinib in cutaneous sarcoidosis (CS) ahead of schedule, targeting 40,000 US patients.

    • Received initial $950 million payment from Moderna settlement, with $200 million in share repurchases in the quarter.

    • Multiple key data readouts expected in H2 2026, including brepocitinib in NIU and 1402 in PH-ILD and CLE.

    Concerns

    4

    • Management noted the quarter was "quiet" with "not the most interesting" earnings call, indicating a period of anticipation rather than significant new disclosures.

    • The company's guidance for brepocitinib DM launch is "slow and steady," suggesting initial uptake may not be rapid.

    • Uncertainty regarding the translatability of PVR reductions from PAH to PH-ILD for 1402, which is a risk for the program.

    • Variability in placebo response rates in immunology trials, particularly for the NIU study, is a concern for future readouts.

    Guidance & targets

    10
    CategoryTargetConfidence
    Brepocitinib launch
    By end of September
    high materiality
    High
    Brepocitinib NIU study top-line data
    Second half of this year
    medium materiality
    High
    1402 PH-ILD Phase II top-line data
    Second half of this year
    medium materiality
    High
    1402 DTRA program update
    Second half of this year
    medium materiality
    High
    CLE POC study top-line data
    Second half of this year
    low materiality
    High
    Brepocitinib cutaneous sarcoidosis Phase III top-line data
    2028
    medium materiality
    High
    Commercial launches
    3 or more
    high materiality
    High
    Business study readouts
    9 or more
    high materiality
    High
    NDA or BLA filings
    4-plus
    high materiality
    High
    Proof-of-concept studies
    A number of
    medium materiality
    High

    Operational metrics

    9
    R&D expense
    $200 million
    Q1 FY27

    R&D expense for the quarter.

    Non-GAAP adjusted G&A expense
    just under $100 million
    Q1 FY27

    Non-GAAP adjusted G&A expense for the quarter.

    GAAP G&A expense
    $166 million
    Q1 FY27

    GAAP G&A expense for the quarter.

    Cash balance
    just under $4 billion
    as of 2026-06-30

    Cash balance before receipt of $72 million.

    Share repurchase
    $200 milliona bit more than that when you include March
    Q1 FY27

    Share repurchase activity in the quarter, accelerated upon Moderna settlement announcement.

    Cutaneous sarcoidosis patient population
    40,000
    current

    Estimated patient population in the U.S. for cutaneous sarcoidosis.

    DM referral centers
    200
    current

    Number of referral centers treating dermatomyositis patients in the U.S.

    Off-label JAK use in DM
    low single-digit percentage or mid-single-digit percentage
    current

    Percentage of dermatomyositis patients with experience using off-label JAK inhibitors.

    CLE POC study design
    600versus placebo
    12 weeks

    Dose and duration of the initial period of the cutaneous lupus erythematosus (CLE) proof-of-concept study.

    Industry KPIs

    5
    MetricValueDetails
    Launch access metrics200 referral centerscenters
    Pipeline read out calendarMultiple readouts
    Regulatory approvals filingsPDUFA date this quarter
    Clinical trial efficacy safety dataGreater than 20-point benefitpoints
    Collaboration milestone royalty revenue$950 millionUSD

    Deals & partnerships

    2
    ModernaPatent litigation settlement$950 million

    Upfront payment received from settlement.

    Pfizer-BioNTechInternational patent lawsuits

    Filed 3 international lawsuits in Canada and UPC in July.

    Risks & headwinds

    4
    Variability in placebo response rates in immunology trialsFor upcoming NIU study readout (H2 2026)

    Significant variability

    Translatability of PVR reductions from PAH to PH-ILD for 1402For upcoming PH-ILD Phase II data readout (H2 2026)

    Not quantified

    Mitigation: Study designed with care around emphysema levels to maximize potential benefit.

    Initial slow uptake for brepocitinib DM launchInitial launch period (Q3 FY27 and beyond)

    Slow and steady

    Mitigation: Focusing on building a strong foundation for access, patient support, and scientific communication for long-term opportunity across multiple indications.

    JAK class safety concerns for brepocitinibOngoing

    Black Box warnings

    Mitigation: Choosing indications like DM where unmet need is high and existing therapies have worse safety profiles; DM patients inherently at risk of some concerns, and treating them well reduces those risks.

    What to watch in Q2 FY27

    5

    Brepocitinib DM launch progress

    Next quarter
    CurrentPDUFA date this quarter, launch expected by end of September.
    TargetInitial commercial uptake and physician/patient feedback.

    Why it matters

    This is the company's first major commercial launch, critical for revenue generation and establishing market presence.

    Obviously, one of the major events in the near term here is the launch -- potential launch of brepocitinib in dermatomyositis.

    Q&A highlights

    5

    What metrics will be provided for the DM launch? For PH-ILD, what are the implications of patients being on nintedanib regarding fibrosis/emphysema ratio and the bar for success (6-minute walk vs. PVR)?

    Roivant will not provide extensive detail on DM launch metrics initially, focusing on internal understanding and patient/physician engagement, with more guidance closer to approval. For PH-ILD, the study design considered emphysema. Management expects a clear PVR signal but does not consider 6-minute walk essential for a go/no-go decision, as the study is not powered for it.

    “I don't know that we're going to provide a ton of detail in the early days. I think it's important for us mostly to spend our time focused on understanding those dynamics ourselves, getting out, talking to patients, talking to physicians, doing the work we need to do.”

    asked by Brian Chin · answered by Matthew Gline

    2 min read6 chapters

    Detailed Narrative

    01

    Brepocitinib Launch Strategy

    Roivant is preparing for the imminent potential launch of brepocitinib in dermatomyositis (DM), emphasizing a "slow and steady" approach. This strategy aims to build a strong foundation for access, patient support, and scientific communication, not just for DM but also for future indications like NIU, cutaneous sarcoidosis (CS), and lichen planopilaris (LPP). The company believes this measured approach will maximize the long-term opportunity across all potential indications, rather than focusing solely on rapid initial uptake in DM.

    02

    Pipeline Progress and Upcoming Catalysts

    The company highlighted significant progress across its pipeline, including the initiation of a Phase III study for brepocitinib in cutaneous sarcoidosis, ahead of schedule. Multiple key data readouts are anticipated in the second half of 2026, including top-line data for brepocitinib in non-infectious uveitis (NIU), 1402 in PH-ILD (pulmonary hypertension associated with interstitial lung disease), and a proof-of-concept study in cutaneous lupus erythematosus (CLE). Updates on the 1402 difficult-to-treat RA program are also expected.

    03

    Cutaneous Sarcoidosis (CS) Program

    The Phase III study for brepocitinib in CS has begun enrolling patients, targeting a high-unmet-need population of approximately 40,000 patients in the US. The study design incorporates learnings from the successful Phase II, which showed a greater than 20-point benefit on the CSAMI scale compared to placebo. The pivotal program is a 16-week, 140-patient study with a primary endpoint of CSAMI >= 50% response rate, with top-line data expected in 2028.

    04

    PH-ILD Program (1402)

    Management discussed the 1402 program for PH-ILD, noting the study's design carefully considered emphysema levels to maximize potential benefit. While the study is not powered for 6-minute walk distance, the focus is on achieving a clear signal on PVR (pulmonary vascular resistance) as an approvable therapy. The translatability of PVR reductions from PAH to PH-ILD is a key question the study aims to answer, with results expected in H2 2026.

    05

    Financial Update and Capital Allocation

    Roivant reported approximately $200 million in R&D expense and $166 million in GAAP G&A for the quarter. The company's cash balance was just under $4 billion, prior to a $72 million receipt. Following the Moderna settlement, Roivant accelerated its share repurchase program, buying back approximately $200 million in shares during the quarter at an average price in the high $20s, demonstrating a commitment to returning capital to shareholders.

    06

    Litigation Updates

    The company received the upfront $950 million payment from the Moderna settlement. Progress continues on the 4098 patent ruling at the Federal Circuit, which could yield an additional $1.3 billion. Roivant also filed three international lawsuits against Pfizer-BioNTech in July, including in Canada and the UPC, actively pursuing potential further recoveries.

    AI-generated summary of the company’s earnings call. Not investment advice.